Anoikis acts as a critical barrier to metastasis by inducing cell death upon cancer cell detachment from the extracellular matrix (ECM), thereby preventing tumor cell dissemination to secondary sites. The induction of anoikis requires the lysosomal-mediated downregulation of epidermal growth factor receptors (EGFRs) leading to termination of pro-survival signaling. In this study, we demonstrate that depletion of pre-mRNA splicing factor 4 kinase (PRP4K; also known as PRPF4B) causes dysregulation of EGFR trafficking and anoikis resistance. We also report a novel cytoplasmic localization of PRP4K at the late endosome, and demonstrate both nuclear and cytoplasmic localization in breast, lung and ovarian cancer tissue. Mechanistically, depletion of PRP4K leads to reduced EGFR degradation following cell detachment from the ECM and correlates with increased TrkB, vimentin and Zeb1 expression. As a result, PRP4K loss promotes sustained growth factor signaling and increased cellular resistance to anoikis in vitro and in a novel zebrafish xenotransplantation model of anoikis sensitivity, as well as increased metastasis in a mouse model of ovarian cancer. Thus, PRP4K may serve as a potential biomarker of anoikis sensitivity in ovarian and other epithelial cancers.
in zebrafish xenografts and increased metastasis in a mouse model of ovarian cancer.

RESULTS
Identification and characterization of a cytoplasmic pool of PRP4K localized to the late endosome
In previous studies, PRP4K was demonstrated to localize to the nucleus within SC35-positive ‘splicing speckles’,9,11,12 consistent with PRP4K’s role in spliceosome assembly.13 However, immuno-histochemistry analysis of PRP4K protein expression in pre-chemotherapy breast, ovarian and lung tumors using tissue microarrays (TMAs) identified both nuclear and a novel cytoplasmic localization of PRP4K (Figure 1a) that was not seen when a peptide was used to block antibody binding (Supplementary Figure 1).

To better evaluate PRP4K subcellular localization in vitro, we used a CRISPR/Cas9 mediated knock-in strategy to generate a HeLa cell line (HeLaClover-PRP4K) expressing the green fluorescent protein clover14 fused to the N-terminus of PRP4K. In-frame insertion of the clover cDNA was confirmed by western blot analysis using an anti-PRP4K antibody following GFP-affinity purification (Figure 1b), and by genomic sequencing (Supplementary Figures 2 and 3). Western blot analysis indicated that only a single allele was targeted in this cell line. Immuno-fluorescence analysis of both live and fixed HeLaClover-PRP4K cells revealed the expected speckle nuclear localization, but also identified a cytoplasmic pool of PRP4K that increased when cells were treated with 50 μM chloroquine (Figure 1c; Supplementary Figure 4). Given that chloroquine prevents endosomal acidification, leading to late endosome/autophagosome accumulation, the increase in cytoplasmic PRP4K following chloroquine treatment suggested an accumulation of this protein within a late endosomal compartment. To test this hypothesis, HeLaClover-PRP4K cells were treated with chloroquine and analyzed for co-localization of endosomal markers via immunofluorescence microscopy (Figure 2). PRP4K co-localized partially with markers of the late endosome (Rab7)15 and autophagosome (p62),16 but showed no co-localization with markers of the early endosome (EEA1 and Rab5).17 In addition, PRP4K-positive cytoplasmic puncta were frequently found adjacent to lysosomes (LAMP2),18 consistent with a lysosome-endosome fusion defect following chloroquine treatment. Taken together, these data identify a novel cytoplasmic localization for PRP4K with enrichment at the late endosome/autophagosome.

Loss of PRP4K impairs EGFR degradation following EGF stimulation
Given the localization of PRP4K to the late endosome/autophagosome, and the important role of endocytic trafficking in regulating EGFR signaling,19,20 we sought to determine whether PRP4K was having a role in endocytic trafficking. Stimulation of HeLaClover-PRP4K cells with EGF resulted in partial co-localization of PRP4K with activated, internalized EGFR (pEGFR) (Supplementary Figure 5) and the late endosome marker, Rab7 (Supplementary Figure 6). To determine if PRP4K was regulating receptor trafficking, we investigated whether depletion of PRP4K by shRNA could affect EGFR degradation following EGF stimulation. Knockdown of PRP4K in HeLa cells did not impact internalization of the activated EGF receptors (Supplementary Figure 7). In contrast, depletion of PRP4K in HeLaClover-PRP4K cells using shRNA significantly decreased EGFR degradation following EGF stimulation (Figure 3). These data indicate that PRP4K plays a role in the degradation of activated EGFR following EGF stimulation.

Figure 1. Cytoplasmic localization of PRP4K. (a) Representative immunostaining of nuclear and cytoplasmic PRP4K in breast, high-grade serous ovarian and lung cancer tissue microarrays. Scale bars, 100 microns. (b) HeLaClover-PRP4K cells were generated using a CRISPR/Cas9 mediated knock-in of a clover tag into the PRPF4B gene locus. Lysates from parental HeLa and HeLaClover-PRP4K cells were subjected to GFP-trap affinity purification and analyzed by western blotting for PRP4K. (c) HeLaClover-PRP4K cells were treated with vehicle or 50 μM chloroquine (CQ) overnight and analyzed by immunofluorescence confocal microscopy using an anti-GFP antibody (Green). Nuclei were stained with DAPI and indicated by the dashed white line. Scale bars, 10 microns. Solid white line identifies the line scan with the corresponding line plot graph displayed to the right. Green line = PRP4K. Blue line = DAPI. Arrowheads indicate cytoplasmic PRP4K signal.
EGFR receptor into endosomes but appeared to inhibit its subsequent degradation, as indicated by the significant retention of phospho-EGFR positive endosomes in the cytoplasm of HeLa shPRP4K cells 90 min after stimulation with EGF (Figures 3a and c). Western blot analysis confirmed a delay in the degradation of EGFR (Figures 3b and d) in PRP4K knockdown cells, which resulted in sustained activation of both Erk, as indicated by increased phospho-Erk (T202/Y204) (Figure 3b), and the Akt pathway as indicated by phospho-Akt (S473) (Figures 3b and e). Degradation of EGFR following EGF stimulation has been shown to induce EGFR biosynthesis21,22 as means of restoring the amount of receptor at the cell surface. Consistent with this, we observed induction of EGFR gene expression in response to EGF treatment in HeLa, MCF-7 and ID8 cells (Supplementary Figure 7). However, knockdown of PRP4K in all three cell lines inhibited induction of EGFR mRNA, consistent with impaired receptor degradation.

Loss of PRP4K increases cellular resistance to anoikis in vitro
The induction of anoikis following ECM detachment is a complex process which includes the downregulation of EGFR leading to the termination of pro-survival signaling via Akt and Erk.6 Cancer cells which have lost the ability to downregulate EGFR6 and human keratinocytes stimulated with EGF23 both escape anoikis when cultured under non-adherent conditions, demonstrating the importance of EGFR activation in anchorage-independent cell growth. Given the EGFR trafficking defect in PRP4K-depleted HeLa cells, we next sought to determine whether PRP4K knockdown could rescue cells from anoikis using ID8 mouse ovarian cancer (Figure 4a) and MCF-7 breast cancer cells (Figure 5a). Although we observed no difference in proliferation of adherent control and knockdown cells (Figures 4b and 5b) or in the expression of Bcl2 or Bcl-xL (Figures 4c and 5c) in either ID8 or MCF-7 cells, loss of PRP4K in ID8 cells under non-adherent conditions resulted in
Figure 3. PRP4K regulates EGF-dependent EGFR degradation. (a) HeLa shCTRL, shPRP4K-1 and shPRP4K-2 cells were serum starved overnight and treated with 50 ng/ml EGF for 30 and 90 min. Cells were fixed and analyzed by immunofluorescence confocal microscopy using an antibody against phospho-EGFR (green). Nuclei were stained with DAPI (blue). White boxes outline the cell shown at an increased magnification directly below. Scale bars, 10 microns. (b) HeLa shCTRL, shPRP4K-1 and shPRP4K-2 cells were serum starved overnight and treated with 50 ng/ml EGF for the indicated time period. Whole-cell lysates were prepared and subject to western blot analysis using the indicated antibodies. (c) Cytoplasmic phospho-EGFR (pEGFR) levels (90 min post-EGF stimulation) were quantified by immunofluorescence microscopy as a percentage of pEGFR staining at 30 min post EGF in each cell line. The points in the scatterplots represent the sum of the mean fluorescence intensity of all cytoplasmic pEGFR puncta per cell from 12 fields of view (z-stack projections of 20 confocal sections captured at 0.4 μm intervals) across three experiments, where each field of view contained 20–25 cells. Error bars = s.e.m. ***P < 0.001. (d) EGFR protein levels (90 min post-EGF stimulation) were quantified using densitometry from western blots and normalized as a percentage of EGFR levels at 0 min in HeLa shCTRL, shPRP4K-1 and shPRP4K-2 cells. Scatterplots represent data from three independent experiments. Error bars = s.d. *P < 0.05; **P < 0.01. (e) P-Akt levels were quantified using densitometry and represented as the mean from three independent experiments. Error bars = s.d. *P < 0.05; ***P < 0.001.
sustained Akt pathway activation (Figure 4c), reduced apoptosis (Figure 4d) and increased viability (Figure 4e), as well as enhanced anchorage-independent growth as multicellular spheroids (Figures 4f and g). Although we did not see a difference in Akt phosphorylation between control and PRP4K-depleted MCF-7 cells when grown in non-adherent conditions, PRP4K knockdown cells did exhibit anoikis resistance as evidenced by reduced apoptosis (Figure 5d) and increased viability in suspension (Figure 5e).

To determine if trafficking of other RTKs was impacted by the loss of PRP4K, we examined protein levels of TrkB, a known driver of anoikis resistance.24 Knockdown of PRP4K in both ID8 (Figure 4c) and MCF-7 (Figure 5c) cells was associated with increased TrkB levels. Since TrkB overexpression can contribute to

---

**Figure 4.** Loss of PRP4K promotes anoikis resistance in ID8 ovarian cancer cells via sustained RTK signaling. (a) ID8 cells were transduced with control or PRP4K targeting shRNA lentiviral vectors to generate cell lines stably expressing the indicated hairpin. Knockdown of PRP4K was confirmed by western blot analysis. (b) In vitro proliferation rates were determined by plating 50,000 cells for each cell line and performing cell counts every 24 h. Data are presented as mean of four independent experiments ± s.d. (c) ID8 shCTRL and shPRP4K cells lines were cultured as attached monolayers or suspended on polyHEMA coated plates for 24 h. Cells were harvested and subject to western blot analysis using the indicated antibodies. (d) The frequency of apoptotic cells in adherent and suspension growth conditions after 24 h was quantified by flow cytometric Annexin-V staining. Error bars = s.e.m. (N = 4). *P < 0.05 (e) Cell viability was also ascertained in non-adherent conditions relative to adherent cell growth over 72 h via AlamarBlue staining. Error bars = s.d. (N = 4). Significance was determined by a two-way ANOVA. ***P < 0.0001 (f) Representative images of ID8 spheroids after 7 days in culture (top). Scale bars, 250 μm. Individual spheroids were harvested, trypsinized, and plated in 6-well plates. After 5 days in culture, colonies were fixed and stained with crystal violet. Representative images show colony growth for each of the three cell lines (bottom). (g) Stained colonies from three independent experiments were counted using ImageJ and represented as the mean colony number. Error bars = s.d. *P < 0.05; ***P < 0.001.
knockdown of PRP4K

Knockdown of PRP4K enhances peritoneal dissemination in a syngeneic mouse model of epithelial ovarian cancer

Acquisition of anoikis resistance is an essential prerequisite for tumor metastasis, particularly in the peritoneal dissemination of ovarian cancer cells. To determine if the increased resistance to anoikis associated with loss of PRP4K in vitro was sufficient to promote dissemination in a mouse model of ovarian cancer, ID8 shCTRL and ID8 shPRP4K cells were injected intraperitoneally into mice and the frequency of tumor nodules and tumor cells in the ascites fluid was assessed 28 days later. Mice injected with ID8 shPRP4K cells had an increased number of metastatic nodules on the diaphragm and peritoneal wall (Figure 7d) and also had an increased number of GFP-positive tumor cells present within the ascitic fluid (Figure 7d). In separate experiments, ID8 shCTRL cells were recovered from the ascites of mice 28 days post injection and examined for their sensitivity to anoikis (Figures 7e–g). As described by Cai and colleagues, ID8 cells isolated from ascites exhibited increased anoikis resistance, which correlated with reduced PRP4K levels and increased Akt phosphorylation in cell lines rescued from 3 of the 4 injected mice (Figure 7h). Similarly, we observed a reduction in PRP4K levels and increased Akt phosphorylation in cell lines rescued from 3 of the 4 injected mice (Figure 7h).

Knockdown of PRP4K also occurs as a consequence of adaptation of ovarian cancer cells to non-adherent growth in vivo, consistent with PRP4K loss playing a role in anoikis resistance. Furthermore, given its role in suppressing anoikis resistance, these data may explain why

epithelial-to-mesenchymal transition (EMT) and is associated with increased expression of EMT-markers vimentin, Snail and Zeb1,25,26 we also surveyed the expression of these and other markers of EMT in control and PRP4K-depleted ID8, MCF-7 and HeLa cells (Supplementary Figure 8). Consistent with upregulation of TrkB, we observed increased expression of Zeb1 in all three cell lines after PRP4K depletion, and vimentin in at least 1 of 2 knockdown lines in ID8 and HeLa cells.

Knockdown of PRP4K increases survival and growth of ID8 cells in zebrafish embryos

To explore the anoikis resistance phenotype associated with knockdown of PRP4K in vivo, we employed a zebrafish xenotransplantation model.27 In this model, human cancer cells are transplanted into the yolk sac of zebrafish embryos at 48 h post fertilization. The yolk sac provides a nutrient-rich acellular environment in which engrafted cells are suspended and, unlike engraftment in tissue, lacks the necessary ECM contacts required to prevent anoikis. ID8 shCTRL and ID8 shPRP4K cells were transplanted into 48 h old zebrafish embryos and cell proliferation visualized by imaging individual embryos at 24 and 72 h post injection (Figure 6a). Cell growth and proliferation were quantified ex vivo in pools of dissociated embryos using fluorescence microscopy.27 Over 48 h post injection, ID8 shCTRL cells grew poorly within embryos, as expected for an anoikis-sensitive epithelial cell line. In contrast, we observed a ~2-fold increase in ID8 shPRP4K cell number over the same time period (Figure 6b), consistent with an increased in vivo resistance to anoikis in PRP4K-depleted ID8 cells.

Knockdown of PRP4K promotes anoikis resistance in MCF-7 breast cancer cells. (a) MCF-7 cells were transduced with control or PRP4K targeting shRNA lentiviral vectors to generate cell lines stably expressing the indicated hairpin. Knockdown of PRP4K was confirmed by western blot analysis. (b) In vitro proliferation rates were determined by plating 50 000 cells for each cell line and performing cell counts every 24 h. Data are presented as mean of four independent experiments ± s.d. (c) MCF-7 shCTRL and shPRP4K cells lines were cultured as attached monolayers or suspended on polyHEMA coated plates for 24 h. Cells were harvested and subject to western blot analysis using the indicated antibodies. (d) The frequency of apoptotic cells in adherent and suspension growth conditions after 24 h was quantified by flow cytometric Annexin-V staining. Error bars = s.e.m. (N = 4). ****P < 0.0001. (e) Cell viability was also ascertained in non-adherent conditions relative to adherent cell growth over 72 h via AlamarBlue staining. Error bars = s.d. (N = 4). Significance was determined by a two-way ANOVA ****P < 0.0001.

Figure 5. Loss of PRP4K promotes anoikis resistance in MCF-7 breast cancer cells. (a) MCF-7 cells were transduced with control or PRP4K targeting shRNA lentiviral vectors to generate cell lines stably expressing the indicated hairpin. Knockdown of PRP4K was confirmed by western blot analysis. (b) In vitro proliferation rates were determined by plating 50 000 cells for each cell line and performing cell counts every 24 h. Data are presented as mean of four independent experiments ± s.d. (c) MCF-7 shCTRL and shPRP4K cells lines were cultured as attached monolayers or suspended on polyHEMA coated plates for 24 h. Cells were harvested and subject to western blot analysis using the indicated antibodies. (d) The frequency of apoptotic cells in adherent and suspension growth conditions after 24 h was quantified by flow cytometric Annexin-V staining. Error bars = s.e.m. (N = 4). ****P < 0.0001. (e) Cell viability was also ascertained in non-adherent conditions relative to adherent cell growth over 72 h via AlamarBlue staining. Error bars = s.d. (N = 4). Significance was determined by a two-way ANOVA ****P < 0.0001.
overexpression or amplification of PRPF4B gene is associated with significantly better overall survival in patients with high-grade serous ovarian cancer (Figure 8).

DISCUSSION
Anoikis acts as a critical barrier to metastasis by inducing apoptosis in tumor cells which have detached from the primary tumor. The disengagement of integrins during detachment from ECM reduces EGFR expression, resulting in suppression of prosurvival signaling, a step necessary for the induction of anoikis. As such, increased expression or activity of EGFR is a common mechanism through which tumor cells evade anoikis. Furthermore, since both EGFR and integrins are capable of signaling from the endosome, trafficking defects which prevent receptor degradation and promote endosomal enrichment following cell detachment can influence anoikis susceptibility. Here, we identify the splicing kinase PRP4K as a novel regulator of EGFR trafficking, where loss of PRP4K is associated with impaired endosomal trafficking and degradation of EGFR resulting in anoikis resistance in vitro and in vivo. Thus, we propose that loss of PRP4K could represent a novel biomarker for anoikis resistance in epithelial cancers.

Cytoplasmic PRP4K localizes to the late endosome and its depletion impairs endosomal trafficking of growth factor receptors leading to Akt activation. PRP4K had initially been reported to localize exclusively in the nucleus with enrichment at SC35-containing splicing speckles. Despite being a nuclear protein during interphase, a cytoplasmic role for this kinase outside of mRNA splicing had been revealed by the study of cells in mitosis, where PRP4K is believed to regulate the spindle assembly checkpoint. In the current study, we employed CRISPR-mediated gene editing to insert a clover fluorescence tag into the PRPF4B gene, enabling direct visualization of PRP4K localization without the limitations associated with indirect immunofluorescence, such as issues with antibody penetration and epitope masking. With this approach, we revealed a novel cytoplasmic localization for PRP4K (Figure 1) with enrichment at late endosomes marked by Rab7 (Figure 2; Supplementary Figure 6). Functionally, we have identified a novel role for PRP4K in the trafficking of EGFR, where PRP4K co-localizes in endosomes containing phospho-EGFR (Supplementary Figure 5), and depletion of PRP4K leads to an endosomal accumulation and reduced degradation of EGFR following EGF stimulation (Figure 3). This reduction in receptor degradation resulted in an increased and sustained activation of the Akt and Erk pathways (Figures 3b and d), which provides a mechanism by which PRP4K-depleted cells overcome anoikis. The activation of Akt by depletion of PRP4K resembles recent results observed following the knockdown of another splicing kinase, SRSP protein kinase 1 (SRPK1). In the SRPK1 study, sustained Akt activation was observed following EGF stimulation in SRPK1 knockout mouse embryonic fibroblasts (MEFs). Similar to PRP4K-depleted ID8 and MCF-7 cells, SRPK1 knockout MEFs also displayed increased anchorage-independent growth. This study by Wang and colleagues also revealed a splicing-independent role for SRPK1, where loss of SRPK1 promoted Akt activation by affecting the interaction of the Akt phosphatase PH domain and leucine rich repeat protein phosphatase 1 (PHLPP1) with Akt. Thus, by affecting endosomal trafficking of growth factor receptors, PRP4K loss appears to activate Akt in a different manner than reported for loss of SRPK1. In addition, in both ID8 and MCF-7 cells, PRP4K depletion triggered an increase in TrkB (Figures 4c and 5c); a known regulator of anoikis resistance. Thus, increased TrkB signaling may also contribute to the anoikis resistance observed with PRP4K loss.

Finally, both PRP4K and SRPK1 have roles in alternative splicing by phosphorylating splicing factors. The novel cytoplasmic localization for PRP4K reported here, the ability of both PRP4K and SRPK1 loss to activate Akt, combined with the known redundancy in SR-protein substrates between the splicing kinases, raises the intriguing possibility that these two kinases may share some degree of functional redundancy that extends beyond the regulation of splicing.

Loss of PRP4K: implications for ascites development, metastasis and treatment resistance in recurrent ovarian cancer
More than one third of ovarian cancer patients present with an accumulation of peritoneal ascites at the time of diagnosis. The accumulation of ascites is believed to result in part from a combination of altered vascular permeability within the tumor microvasculature and tumor-mediated obstruction of lymphatic drainage. Management of ascites is generally limited to treatment of the underlying disease with platinum and taxane-based chemotherapy. While the clinical response to first-line chemotherapy is quite high, ranging from 70 to 80%, the
majority of patients (50–75%) relapse due to the development of chemoresistance. In most cases, recurrent disease is accompanied by intractable ascites that likely arises from increased peritoneal transcoelomic metastases and requires frequent paracentesis for temporary relief of symptoms.

Our previous study identified PRP4K as a HER2-regulated modifier of taxane sensitivity in breast and ovarian cancer. PRP4K levels were shown to decrease in cells that had acquired resistance to taxanes, both in vitro and in vivo. In addition, our previous study demonstrated that low PRP4K expression in ovarian tumors was strongly associated with disease progression and poor survival outcomes in a cohort of taxane-treated serous ovarian cancer patients with low HER2 receptor expression. Data provided in the current study demonstrated that depletion of PRP4K loss drives anoikis resistance.
PRP4K protein levels increased cellular resistance to anoikis in zebrafish ovarian cancer xenografts (Figure 6) and promoted metastasis in the ID8 mouse model of ovarian cancer (Figures 7a–d). Furthermore, we found that cancer cells harvested from the ascites of 3 out of 4 mice, and 3 out of 4 human patients with ovarian cancer, exhibited reduced PRP4K expression (Figures 7e–h), and that the ID8 ascites-derived mouse ovarian cancer cells had increased survival under non-adherent growth conditions in vitro (Figures 7e–h). These results mirror the associated loss of PRP4K expression in cancer cell lines treated with taxanes in vitro and in patient tumors following taxane treatment. Combining our previous work with the current study, we believe we have uncovered one potential mechanism whereby acquired resistance to taxanes through the loss of PRP4K is accompanied by increased anoikis resistance that could in turn promote transcoelomic metastasis and ascites development. In agreement with a possible tumor suppressor role of PRP4K in ovarian cancer, analysis of TCGA data indicated that both amplification of the PRPF4B gene and its overexpression (>2 SD from the mean) were associated with significantly better overall survival (Figure 8). As such, future clinical studies employing PRP4K as a biomarker for prediction of ovarian cancer progression and survival post-taxane therapy may be warranted.

**MATERIALS AND METHODS**

**Patient samples, TMA and immunohistochemistry**

Patient-derived cell lines from primary tumors and ascites were described previously. PRP4K staining of the breast and ovarian cancer TMAs has also been described previously, and lung staining was carried out as described in Corkery et al. The ovarian and breast studies were approved by the institutional ethics board at the Université de Montréal (Montreal, Canada), and the lung study was approved by the ethics committee of the Queen Elizabeth II (QEI) Hospital/Nov Scotia Health District (Halifax, Canada). Tumors were collected and banked following appropriate written informed consent from patients undergoing surgery within the hospital sites. The ovarian cancer TMA was made using 196 high-grade serous ovarian cancer tumor cases in duplicate cores of 0.6 mm diameter. The breast cancer TMA was made using 150 cases of breast cancer. The lung cancer TMA consisted of 332 tumors taken from primary surgical cases of non-small cell lung carcinoma (3%).

Cell culture and shRNA lentiviral transduction

HeLa (ATCC) and ID8 (Dr. Paul Terranova, University of Kansas Medical Center) cells were cultured in Dulbecco’s modified Eagle’s medium (Sigma, Oakville, ON, Canada) supplemented with 10% fetal calf serum, 1% penicillin/streptomycin at 37 °C with 5% CO2. To generate the ID8 GIPZ shPRP4K and HeLa TRIPZ shPRP4K cell lines, GIPZ (shPRP4K-1 = clone: V3LMM_463188, shPRP4K-1 = clone: V3LMM_463189, Non-silencing shCTRL = RHS4346) and TRIPZ (shPRP4K-1 = clone: V2THS_47787, shPRP4K-2 = clone: V3LMM_383960, Non-silencing shCTRL = RHS4743) lentiviral shRNAs were purchased from Thermo Scientific (Burlington, ON, Canada). Lentivirus was produced by co-transfection of the GIPZ/TRIPZ plasmids with pMD2.G, pCMV-8.92 and pCMV-8.93 lentiviral packaging vectors into human HEK-293 T cells via calcium-phosphate transfection (Promega, Madison, WI, USA) as described previously. After 48 h, viral media from the transfected cells was filtered (0.45 µm) filter) and added to the target cells for 24 h, after which cells were allowed to recover for 24 h in fresh media before selection in media containing 2 µg/ml puromycin, 4–5 days. To induce expression of the TRIPZ PRP4K shRNA in HeLa cells, 2 µg/ml doxycycline was added to culture media for 72–96 h before experimentation with the drug being replaced every 24 h. MCF-7 shCTRL and shPRP4K-1 and 2 cell lines are described in detail in.

For EGF stimulation, HeLa shCTRL/shPRP4K cells were serum starved overnight using DMEM containing 0.25% FBS, followed by treatment with 50 ng/ml EGF (Sigma) for the indicated time period.

**Generation of the HeLa**

Cell culture and Western blot analysis

Cells were lysed in ice-cold lysis buffer (20 mM Tris-HCl pH 8, 300 mM KCl, 10% glycerol, 0.25% NP-40, 0.5 mM EDTA, 0.5 mM EGTA, 1× protease inhibitors) and lysates cleared by centrifugation (25 min, 15 000 × g, 4 °C) before PAGE and western blotting as previously described. Primary antibodies used for western blot analysis were used at the dilution recommended by the manufacturer unless noted, and included a custom PRP4K antibody (H143, 1:1000) antibodies from Cell Signaling (Danvers, MA, USA), anti-EGFR (#4267, 1:2000), anti-Akt (pan) (#4691, 1:2000), anti-p-Akt (Ser473) (#4060, 1:2000), anti-Erk (#4695), anti-β-actin (#4267, 1:2000), anti-Erk (#4695), anti-β-actin (#4267, 1:2000), and antibodies in the EMT sampler kit (#9782); Sigma, anti-actin (A2228) (1:5000); and Santa Cruz (Santa Cruz, CA, USA), anti-Trk (sc-37721). Secondary antibodies used include HRP-conjugated goat anti-rabbit IgG (Sigma, A6154), HRP-conjugated goat anti-mouse IgG (Sigma, A5424), and HRP-conjugated sheep anti-rabbit IgG (Sigma, A6154). HRP-conjugated sheep anti-rabbit IgG (Sigma, A6154).
anti-mouse IgG (Sigma, A5906) and HRP-conjugated donkey anti-sheep IgG (Sigma, A3415).

Immunofluorescence microscopy and live-cell imaging

HeLaClover PRP4K cells were plated onto glass coverslips in a 6-well plate and treated overnight with 50 μM chloroquine (Sigma) or stimulated with EGF as above. Cells were fixed with 4% paraformaldehyde in PBS for 10 min at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 10 min and immunolabeling was carried out as previously described.10 Fluorescent images were captured with a Zeiss Cell Observer spinning-disc microscope (Intelligent Imaging Innovations, 3i, Boulder, CO, USA) using a 1.4 NA 63 × immersion oil objective lens. Images were processed using only linear adjustments in Adobe Photoshop CS5 and Slidebook (3i) software, which was also used for the analysis of mean fluorescence intensity of immunostaining.

Antibodies used for immunofluorescence were used at the manufacturers recommended dilution unless otherwise noted, and include anti-GFP (Abcam, Toronto, ON, Canada, ab13970) (1:2000 dilution), anti-EEA1 (Cell Signaling, #3288) (1:100 dilution), anti-Rab5 (Cell Signaling, #3547) (1:200 dilution), anti-Rab7 (Cell Signaling, #9367) (1:100 dilution), anti-p62 (Cell Signaling, #7695) (1:400 dilution), anti-LAMP2 (Abcam, ab25631) (1:200 dilution), and anti-p-EGFR (Tyr1068) (Cell Signaling, #3777) (1:800 dilution).

Quantification of in vitro proliferation rates

To determine the in vitro proliferation rates of ID8 and MCF-7 shCTRL, shPRP4K-1 and shPRP4K-2 cells, 50,000 cells were plated in individual wells of a 6-well plate. Cells were trypsinized and counted at 24 and 48 h after plating.

Spheroid cell growth, viability and anoikis assays

Spheroids assays were conducted in 6-well plates as described previously63 and images of each well were captured with a digital camera and the number of colonies quantified using ImageJ (NIH, Bethesda, MA, USA). For anoikis assays, poly 2-hydroxyethyl methacrylate (PolyHEMA) (Sigma, P3932) was dissolved in 95% ethanol (20 mg/ml) at 65 °C and used to coat tissue culture plates (4 ml per 10 cm plate) dried overnight at 37 °C. P3932) was dissolved in 95% ethanol (20 mg/ml) at 65 °C and used to coat tissue culture plates (4 ml per 10 cm plate) dried overnight at 37 °C. Cells were plated on PolyHEMA coated and non-coated tissue culture dishes for 24 h and then harvested for western blot analysis, cell viability assays using AlamarBlue (DAL1100, Life Technologies, Mississauga, ON, Canada), and apoptosis assays using allopoxycocyanin-conjugated Annexin-V (eBioscience, Mississauga, ON, Canada) and flow cytometry (FACSCalibur flow cytometer, BD Biosciences, Mississauga, ON, Canada) as described previously.64 Flow cytometry data was analyzed using FlowJo (V10.2; FlowJo, Ashland, OR, USA).

Zebrafish xenotransplantation

All zebrafish studies were approved by the Dalhousie University Committee on Laboratory Animals. ID8 shCTRL or ID8 shPRP4K cells labeled with the lipophilic cell tracking dye, CM-Dil (Thermo Scientific) were injected (25–50 cells) into the yolk sac of 48 h casper zebrafish embryos. Embryos were imaged and enzymatically dissociated to quantify cancer cell growth at 24 and 72 h post injection as described previously.

Mouse experiments

All experimental procedures were approved by the Dalhousie University Committee on Laboratory Animals following the guidelines of the Canadian Council on Animal Care. Two groups of 5, 8-10 week old female C57/B6J mice (Charles River Laboratories) were injected i.p with 3 x 10⁶ ID8 shCTRL or ID8 shPRP4K cells, without specific randomization or blinding. The frequency of tumor nodules and tumor cells in the ascites was assessed 28 days later.

Statistical analyses

For animal studies, an unpaired T-test was used; where an s.d. of 10% was assumed and 5 animals per group was expected to detect a 20% difference with a power of 0.8 (StatMate 2.00 by GraphPad, La Jolla, CA, USA). Normality of data was determined by Shapiro–Wilk test (http://sdstatti. altervista.org/shapiroTest/ShapiroTest.html). Kaplan–Meier curve analysis and Student’s T-test (2-sided) were carried out using GraphPad Prism 7.03. Statistical significance was set at P = 0.05.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank the Gynecology-Oncology and Pathology services of the CHUM-Hôpital Notre-Dame for tumor procurement, Gretchen Wagner for fish care, and Monique Bernard for technical assistance. ovarian and breast tumor banking was supported by the Cancer Research Network Tissue Bank of the Fonds de recherche du Québec—Santé (FROS). This work was funded by research grants from the Canadian Breast Cancer Foundation (CBCF) and the Breast Cancer Society/Québec Foundation awarded to GD, and research grants to BJ from the Canadian Institutes of Health Research (CIHR) (MOP-110988, PJT-153245). GD, JB and BJ are Senior Scientists of the Beatrice Hunter Cancer Research Institute (BHCR)., and DPC, LC, JS and JP were supported by trainee awards from the BHCR with funds provided by CBCF—Atlantic, The Canadian Cancer Society, Nova Scotia Division as part of The Terry Fox Foundation Strategic Health Research Training (STIHR) Program in Cancer Research at the CIHR. SG is the recipient of doctoral awards from the Killam Trusts, CIHR, and BHCR.

REFERENCES

1. Frisch SM, Francis H. disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619–626.
2. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997; 9: 701–706.
3. Giancotti FG. Complexity and specificity of integrin signalling. Nat Cell Biol 2000; 2: E13–E14.
4. Galbarr-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003; 22: 359–374.
5. Moro L, Venturino M, Bozzo C, Silengo L, Alturda F, Beguinot L et al. Integrins induction of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J 1998; 17: 6622–6632.
6. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J et al. Integrins and EGF/f regulate coordinate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003; 5: 733–740.
7. Grassian AR, Schaffer ZT, Brugge JS. ErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cells. J Biol Chem 2011; 286: 79–90.
8. Rosenberg GH, Alahari SK, Kaufner NF. pp4 from Schizosaccharomyces pombe, a mutant deficient in pre-mRNA splicing isolated using genes containing artificial introns. Mol Gen Genet 1991; 236: 305–309.
9. Dellaire G, Makarov EM, Cowger JM, Longman D, Sutherland HGE, Luhrmann R et al. Mammalian PRP4 kinase copurifies and interacts with components of both the US snRNPs and the N-CoR decetylase complexes. Mol Cell Biol 2002; 22: 5141–5156.
10. Carkery DP, Le Page C, Meunier L, Provencer D, Mes-Massom AM, Dellaire G. PRP4K is a HER2-regulated modulator of taxane sensitivity. Cell Cycle 2015; 14: 1059–1069.
11. Kojima T, Zama T, Wada K, Onoqi H, Hagiwara M. Cloning of human PRP4 reveals interaction with Ctk1. J Biol Chem 2001; 276: 32247–32256.
12. Montembault E, Dutertre S, Prigent C, Giet R. PRP4 is a spindle assembly checkpoint protein required for MPS1, MAD1, and MAD2 localization to the kinetochores. J Cell Biol 2007; 179: 601–609.
13. Schneider M, Hisao HH, Will CL, Giet R, Urlaub H. PRP4 kinase is required for stable tri-snRNP association during spliceosomal B complex formation. Nat Struct Mol Biol 2010; 17: 216–221.
14. Lam AJ, St-Pierre F, Gong Y, Marshall JD, Crampl PJ, Baird MA et al. Improving FRET dynamic range with bright green and red fluorescent proteins. Nat Methods 2012; 9: 1005–1012.
15. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001; 2: 107–117.
16. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outezen H et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282: 24131–24145.
17 Christoforidis S, McBride HM, Burgoyne RD, Zerial M. The Rab5 effector EEA1 is a core component of endosome docking. Nature 1999; 397: 621–625.

18 Eskenlin EL, Tanaka Y, Saifig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003; 13: 137–145.

19 Wiley HS, Herbst JJ, Walsh BJ, Lauflenburger DA, Rosenfeld MG, Gill GN. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem 1991; 266: 11083–11094.

20 Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 2014; 24: 26–34.

21 Scharaw S, Iskar M, Ari O, Boncompain G, Laketa V, Poser I et al. The endosomal transcriptional regulator RNF11 integrates degradation and transport of EGFR. J Cell Biol 2016; 215: 543–558.

22 Earp HS, Austin KS, Blaisdell J, Rubin RA, Nelson KG, Lee LW et al. Epidermal growth factor (EGF) stimulates EGF receptor synthesis. J Biol Chem 1986; 261: 4777–4785.

23 Jost M, Huggett TM, Kari C, Rodeck U. Matrix-independent survival of human keratinocytes through an EGF receptor/MPK5/kinase-dependent pathway. Mol Biol Cell 2001; 12: 1519–1527.

24 Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. PRP4K loss drives anoikis resistance. Oncogene (2018) 174: 609–615.

25 Smit MA, Peeper DS. Zeb1 is required for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis and metastasis. J Cell Biol 2011; 194: 1455–1468.

26 Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis and metastasis. J Cell Biol 2011; 194: 1455–1468.

27 Christoforidis S, McBride HM, Burgoyne RD, Zerial M. The Rab5 effector EEA1 is a core component of endosome docking. Nature 1999; 397: 621–625.

28 Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis and metastasis. J Cell Biol 2011; 194: 1455–1468.

29 Cai Q, Yan L, Xu Y. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Cancer Res 2018; 78: 1015–1015.

30 Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 2014; 1833: 3481–3489.

31 Rosen K, Coll ML, Li A, Filmus J. Transforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. J Biol Chem 2002; 277: 37273–37279.

32 Nguyen LN, Holdren MS, Nguyen AP, Furuya MH, Bianchini M, Levy E et al. Polymorphisms in the CYBA gene form a haplotype associated with decreased regulation of the epidermal growth factor receptor. Nat Genet 1999; 22: 1754–1759.

33 Christoforidis S, McBride HM, Burgoyne RD, Zerial M. The Rab5 effector EEA1 is a core component of endosome docking. Nature 1999; 397: 621–625.

34 Plasma and Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 2014; 1833: 3481–3489.

35 Nguyen LN, Holdren MS, Nguyen AP, Furuya MH, Bianchini M, Levy E et al. Integrin endosomal signalling suppresses anoikis. Nat Cell Biol 2015; 17: 1412–1412.

36 Angeliki L, Smaila S, Sellars P, Coyle AB, O’Shaughnessy F. Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Biol Cell 2006; 20: 1754–1769.

37 Khwaja A, Rodriguez-Viciana P, Wernstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997; 16: 2783–2793.

38 Wang P, Zhou Z, Hu A, Ponte de Albuquerque C, Zhou Y, Hong L et al. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell 2014; 54: 378–391.

39 Gross T, Lutzelterberger M, Weigmann H, Klingenhoff A, Shenyos S, Kaefer NF. Functional analysis of the fission yeast Prp4 protein kinase involved in pre-mRNA splicing and isolation of a putative mammalian homologue. Nucleic Acids Res 1997; 25: 1028–1035.

40 Gui JF, Lane WS, Fu XD. A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Nature 1994; 369: 678–682.

41 Kataoka N, Bachorik JL, Dreyfuss G. Transportin-SR, a nuclear import receptor for SR proteins. J Cell Biol 1999; 145: 1145–1152.

42 Lai MC, Lin RI, Tam WP. Transportin-SR2 mediates nuclear import of phosphorylated SR proteins. Proc Natl Acad Sci USA 2001; 98: 10154–10159.

43 Lai MC, Lin RI, Huang SY, Tsai CW, Tam WY. A human importin-beta family protein, transportin-SR2, interacts with the phosphorylated RS domain of SR proteins. J Biol Chem 2000; 275: 7950–7957.